Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:QDEL
CUSIP74838J10
Phone858-552-1100
Debt
Debt-to-Equity Ratio0.40
Current Ratio1.36
Quick Ratio1.06
Price-To-Earnings
Trailing P/E Ratio-1,013.71
Forward P/E Ratio30.85
P/E Growth1.2
Sales & Book Value
Annual Sales$277.74 million
Price / Sales9.57
Cash Flow$1.1170 per share
Price / Cash63.52
Book Value$6.68 per share
Price / Book10.62
Profitability
EPS (Most Recent Fiscal Year)($0.07)
Net Income$-8,160,000.00
Net Margins3.08%
Return on Equity12.54%
Return on Assets4.75%
Miscellaneous
Employees1,193
Outstanding Shares37,460,000
Market Cap$2,590.83
Quidel (NASDAQ:QDEL) Frequently Asked Questions
What is Quidel's stock symbol?
Quidel trades on the NASDAQ under the ticker symbol "QDEL."
How were Quidel's earnings last quarter?
Quidel Co. (NASDAQ:QDEL) issued its earnings results on Tuesday, May, 8th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.28. The business earned $169.10 million during the quarter, compared to analysts' expectations of $151.50 million. Quidel had a net margin of 3.08% and a return on equity of 12.54%. The business's revenue for the quarter was up 129.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.45 earnings per share. View Quidel's Earnings History.
When is Quidel's next earnings date?
What price target have analysts set for QDEL?
8 analysts have issued 1 year target prices for Quidel's shares. Their predictions range from $47.00 to $65.00. On average, they anticipate Quidel's stock price to reach $58.8333 in the next twelve months. This suggests that the stock has a possible downside of 17.1%. View Analyst Ratings for Quidel.
What is the consensus analysts' recommendation for Quidel?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 6 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Quidel's key competitors?
Some companies that are related to Quidel include Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER).
Who are Quidel's key executives?
Quidel's management team includes the folowing people:
- Mr. Douglas C. Bryant, Pres, CEO & Director (Age 60)
- Mr. Randall J. Steward, Chief Financial Officer (Age 64)
- Mr. Robert J. Bujarski, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 50)
- Dr. Werner Kroll, Sr. VP of R&D (Age 61)
- Mr. Edward Keith Russell, Sr. VP of North America Operations (Age 50)
Has Quidel been receiving favorable news coverage?
News headlines about QDEL stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quidel earned a daily sentiment score of 0.13 on Accern's scale. They also gave news articles about the company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Quidel's major shareholders?
Quidel's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.09%), Campbell & CO Investment Adviser LLC (0.01%) and Winslow Evans & Crocker Inc. (0.01%). Company insiders that own Quidel stock include Douglas C Bryant, Edward Keith Russell, Jack W Schuler, John Tamerius, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel.
Which institutional investors are selling Quidel stock?
QDEL stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. Company insiders that have sold Quidel company stock in the last year include Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Insider Buying and Selling for Quidel.
Which institutional investors are buying Quidel stock?
How do I buy shares of Quidel?
Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quidel's stock price today?
One share of QDEL stock can currently be purchased for approximately $70.95.
How big of a company is Quidel?
Quidel has a market capitalization of $2.59 billion and generates $277.74 million in revenue each year. The company earns $-8,160,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Quidel employs 1,193 workers across the globe.
How can I contact Quidel?
Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected]
MarketBeat Community Rating for Quidel (NASDAQ QDEL)
MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
